Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7012343 | 0.82 | CHRNA1 (0.50) | ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL7006302 | 0.77 | CHRNB2 (0.57) | ALDH1A1CHRNB2CHRNA4KDM4E | |
| SCHEMBL4554100 | 0.74 | CHRNB2 (0.56) | ALDH1A1CHRNB2CHRNA4KDM4E | |
| SCHEMBL12049097 | 0.74 | CHRNB2 (0.51) | ALDH1A1CHRNB2CHRNA4HRH1KDM4E | |
| SCHEMBL12334539 | 0.72 | HRH3 (0.59) | ALDH1A1CHRNB2CHRNA4KDM4E | |
| SCHEMBL7011440 | 0.72 | CHRNB2 (0.33) | ALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL789428 | 0.70 | GABRA1 (0.42) | GABRA1GABRA5CHRM1PRMT5WDR77 | |
| Water SCHEMBL28218487 | 0.69 | LMNA (0.44) | ALDH1A1LMNA | |
| SCHEMBL14308131 | 0.68 | LMNA (0.54) | ALDH1A1KDM4ELMNA | |
| SCHEMBL1666554 | 0.68 | ALDH1A1 (0.61) | ALDH1A1HRH1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100769-A1 | Cyclic amidine compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-05-29 | — | — | US | claimed |
| US-20030100769-A1 | Cyclic amidine compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-05-29 | — | — | US | disclosed |
| EP-1280793-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001081334-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100769-A1 | Cyclic amidine compounds | CHRM1, CHRM5, CCKAR | GABRA1 409/4885GABRA5 411/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.